Evidence map›Paper›PMID 39052128›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Impact of dexamethasone on transplant-related mortality in pediatric patients: a multi-site, propensity score-weighted, retrospective assessment.

Edric Paw Cho Sing, George A Tomlinson, Tal Schechter, Muhammad Ali, Rachel Phelan, S Rod Rassekh, Krista McKinnon, Gefen Aldouby Bier, Marianne van de Wetering, Sergio Gomez and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Edric Paw Cho SingNeonatal and Pediatric Pharmacy, Surrey Memorial Hospital, Surrey, BC, Canada.
George A TomlinsonDepartment of Medicine, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
Tal SchechterDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada.
Muhammad AliDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada.
Rachel PhelanDivision of Hematology and Oncology, Department of Pediatrics, Medical College of Wisconsin, Madison, USA.
S Rod RassekhDivision of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of British Columbia, Vancouver, Canada.
Krista McKinnonPharmacy Services, Alberta Children's Hospital, Calgary, AB, Canada.
Gefen Aldouby BierDivision of Clinical Pharmacy, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem and Department of Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Marianne van de WeteringPaediatric Oncology Department, Princess Máxima Center for Paediatric Oncology, Utrecht, The Netherlands.
Sergio GomezStem Cell Transplantation Unit, Hospital de Niños Sor Maria Ludovica, La Plata, Argentina.
Lillian SungDivision of Haematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada.
L Lee DupuisChild Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada. lee.dupuis@utoronto.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dexamethasone use during hematopoietic cell transplant (HCT) conditioning varies between pediatric centers. This study aimed to estimate the difference in 1-year treatment-related mortality (TRM) between patients who did or did not receive dexamethasone during HCT conditioning. Secondary objectives were to estimate the difference between dexamethasone-exposed and dexamethasone-unexposed groups in 1-year event-free survival (EFS), time to neutrophil engraftment, acute graft-versus-host disease (aGVHD), and invasive fungal disease (IFD) at day + 100. This was a seven-site, international, retrospective cohort study. Patients < 18 years old undergoing their first allogeneic or autologous myeloablative HCT for hematologic malignancy or aplastic anemia between January 1, 2012, and July 31, 2017, were included. To control for potential confounders, propensity score weighting was used to calculate the standardized mean difference for all endpoints. Among 242 patients, 140 received dexamethasone during HCT conditioning and 102 did not. TRM was unaffected by dexamethasone exposure (1.7%; 95% CI - 7.4, 10.2%). Between-group differences in secondary outcomes were small. However, dexamethasone exposure significantly increased possible, probable, and proven IFD incidence (9.0%, 95% CI 0.8, 17.3%). TRM is not increased in pediatric patients who receive dexamethasone during HCT conditioning. Clinicians should consider potential IFD risk when selecting chemotherapy-induced vomiting prophylaxis for pediatric HCT patients.

Indexed as

DexamethasoneHematopoietic Stem Cell TransplantationPropensity ScoreAdolescentChildChild, PreschoolCohort StudiesFemaleGraft vs Host DiseaseHematologic NeoplasmsHumansInfantMaleRetrospective StudiesTransplantation ConditioningDexamethasoneChemotherapy-induced vomitingDexamethasoneHematopoietic cell transplantPediatricsTreatment-related mortality

Identifiers

PMID39052128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.